Get the Stockscreener App
0.489
2.71%
0.0129
Harvard Bioscience Inc stock is traded at $0.489, with a volume of 401.62K.
It is up +2.71% in the last 24 hours and up +10.38% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.4761
Open:
$0.4857
24h Volume:
401.62K
Relative Volume:
0.04
Market Cap:
$21.78M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-2.445
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
-7.56%
1M Performance:
+10.38%
6M Performance:
-50.61%
1Y Performance:
-82.78%
1-Day Range:
$0.4838
$0.5199
1-Week Range:
$0.4685
$0.5357
52-Week Range:
$0.2813
$3.27
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.489 | 22.47M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience announces CEO succession plan - MSN
What is the earnings history of Harvard Bioscience Inc.2025 Price Targets & Safe Capital Investment Plans - classian.co.kr
Relative strength of Harvard Bioscience Inc. in sector analysisWeekly Trade Report & Community Consensus Picks - Newser
Is Harvard Bioscience Inc. showing signs of accumulationMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Harvard Bioscience Inc. stock daily chart insightsAnalyst Downgrade & Long Hold Capital Preservation Tips - Newser
Harvard Bioscience Inc. stock outlook for YEARMarket Growth Report & Reliable Price Breakout Alerts - Newser
What the charts say about Harvard Bioscience Inc. todayOptions Play & Daily Profit Focused Stock Screening - Newser
How Harvard Bioscience Inc. stock performs during market volatility2025 Earnings Surprises & Weekly Market Pulse Alerts - beatles.ru
Why Harvard Bioscience Inc. stock attracts strong analyst attention2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
Harvard Bioscience, Inc. (NASDAQ:HBIO) Held Back By Insufficient Growth Even After Shares Climb 31% - 富途牛牛
Harvard Bioscience Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Chart overlay techniques for tracking Harvard Bioscience Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - Newser
Identifying reversal signals in Harvard Bioscience Inc.2025 Volume Leaders & Weekly Stock Performance Updates - Newser
Real time scanner hits for Harvard Bioscience Inc. explained2025 EndofYear Setup & Precise Swing Trade Alerts - Newser
Is Harvard Bioscience Inc. a stock for growth or value investorsJuly 2025 Trade Ideas & Fast Entry High Yield Tips - newsyoung.net
Harvard Bioscience Offers CFO $100K Retention Bonus Amid Financial Challenges. - AInvest
Order Flow Trends Show Accumulation in Harvard Bioscience Inc.Short Term Alpha Signals Prediction - beatles.ru
What makes Harvard Bioscience Inc. stock price move sharplyWeekly Risk Report & Community Consensus Picks - Newser
Is Harvard Bioscience Inc. a good stock for dollar cost averagingMarket Weekly Review & Short-Term Swing Trade Alerts - sundaytimes.kr
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target - simplywall.st
Can Harvard Bioscience Inc. Overcome Bearish Sentiment2025 Growth vs Value & Intraday High Probability Alerts - beatles.ru
Harvard Bioscience enters retention agreement with interim CFO Mark Frost By Investing.com - Investing.com Nigeria
Harvard Bioscience enters retention agreement with interim CFO Mark Frost - Investing.com
Harvard Bioscience Offers CFO $100K Retention Bonus - TipRanks
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Harvard Bioscience at Risk of Nasdaq Delisting: Implications for Investors and Business Stability - TipRanks
Relative strength of Harvard Bioscience Inc. in sector analysis [2025 Market Overview]Long-Term Capital Growth Ideas - Newser
Harvard Bioscience 2025 Q2 Earnings Narrows Losses with 22% Drop in Net Loss - AInvest
Harvard Bioscience Amends Credit Agreement with Lenders Amid Concerns Over Future Operations - AInvest
Harvard Bioscience: Q2 Earnings Snapshot - Connecticut Post
Is Now a Good Time to Reenter Harvard Bioscience Inc.Target Return Focused Trade Insights Shared - sundaytimes.kr
Harvard Bioscience Inc (HBIO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Harvard Bioscience Inc (HBIO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Harvard Bioscience Reports Q2 2025 Financial Results - TipRanks
Harvard Bioscience Q2 2025: Unpacking Contradictions in NIH Funding, Refinance Terms, and China Market Outlook - AInvest
Harvard Bioscience Surpasses Revenue Guidance Amid Challenges - TipRanks
Harvard Bioscience Amends Credit Agreement with Lenders - TipRanks
Harvard Bioscience Delivers Steady Results And Eyes Growth Ahead - Finimize
Harvard Bioscience Delivers Steady Results And Improved Cash Flow - Finimize
Harvard Bioscience outlines $19M–$21M Q3 revenue target as debt refinancing advances and product adoption accelerates - MSN
Harvard Bioscience, Inc. Enters into Sixth Amendment to the Credit Agreement - MarketScreener
Harvard Bioscience Q2 2025 Earnings Call Transcript - MarketBeat
Harvard Bioscience Exceeds Revenue Estimate in Q2 2025, Reports $20.5 Million in Revenue and a Loss Per Share of $0.05 - AInvest
Harvard Bioscience: Navigating Debt and Innovation in the Biotech Tools Sector - AInvest
Harvard Bioscience sets Q3 revenue target at $19M-$21M, CEO outlines priorities for 2025. - AInvest
Harvard Bioscience earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Earnings call transcript: Harvard Bioscience Q2 2025 results show mixed signals - Investing.com Nigeria
Transcript : Harvard Bioscience, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges By Investing.com - Investing.com South Africa
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges - Investing.com Nigeria
Harvard Bioscience's Q2 2025 Performance: A Strategic Turnaround Amid Debt Refinancing Challenges - AInvest
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):